Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2.

Hopper JL, Jenkins MA.

Am J Hum Genet. 1999 Dec;65(6):1771-6. No abstract available.

2.

Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. Review.

PMID:
10985881
3.

Breast & ovarian cancer. Issues in risk assessment.

Caro SW.

Adv Nurse Pract. 1999 Aug;7(8):26-32; quiz 33-4. Review. No abstract available.

PMID:
10745719
4.
5.

Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.

Rebbeck TR.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):100S-3S. Review.

PMID:
11060335
6.

Chemoprevention options for BRCA1 and BRCA2 mutation carriers.

Eeles RA, Powles TJ.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):93S-9S. Review.

PMID:
11060334
7.

The BRCA paradox in breast and ovarian cancer.

Ponzone R, Baum M.

Eur J Cancer. 1998 Jun;34(7):966-7. Review. No abstract available.

PMID:
9849441
8.

Founder populations and their uses for breast cancer genetics.

Neuhausen SL.

Breast Cancer Res. 2000;2(2):77-81. Review.

9.

Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.

Neuhausen SL, Ostrander EA.

Genet Test. 1997;1(2):75-83. Review.

PMID:
10464630
10.

Forth nightly review: hereditary ovarian carcinoma.

Kasprzak L, Foulkes WD, Shelling AN.

BMJ. 1999 Mar 20;318(7186):786-9. Review. No abstract available.

11.

[Genetic alterations in familial and sporadic breast cancers].

Emi M, Iida A, Kasumi F, Nakamura Y.

Gan To Kagaku Ryoho. 1996 Mar;23 Suppl 1:80-3. Review. Japanese. No abstract available.

PMID:
8702317
Items per page

Supplemental Content

Support Center